| Name | Title | Contact Details |
|---|
Looking for a way to get fit? Explore the world’s best collection of health news and articles for a healthier lifestyle.
Ampio is an innovative drug discovery and development company combining scientific, regulatory, and business capabilities to efficiently develop a robust portfolio of novel therapeutic candidates. These therapeutic candidates, if approved, will address significant inflammatory conditions for which limited treatment options exist. Ampio’s therapeutic product pipeline has been developed through more than two decades of study at leading hospital-based research centers. Rigorous preclinical and clinical research efforts have yielded a diverse portfolio of late-stage product candidates focusing on the world’s most prevalent inflammatory conditions including osteoarthritis and diabetic macular edema. Significant discoveries in both basic science and clinical research have resulted in Ampio receiving over 180 patents throughout the world, with hundreds more pending. Further, hundreds of peer-reviewed publications, abstracts, and scientific presentations highlight the depth of research supporting Ampio’s therapeutic product candidates. Ampio’s leading product candidates are Ampion™ and Optina™. The company is currently conducting the second pivotal clinical trial in the US for Ampion, a biologic intra-articular injection being studied for the treatment of osteoarthritis of the knee. Ampio is also conducting a late-stage US clinical trial for Optina, an oral agent being studied for the treatment of diabetic macular edema. Millions of patients worldwide are affected by these conditions, for which limited treatment options exist. At Ampio, we strive to offer compelling therapeutic options for the patients most in need of new treatments, and we operate every day to advance our products’ development and make these available to patients.
Biosign Technologies Inc. engages in the development, manufacture, and sale of medical devices and information systems. The company provides cloud based systems for non-invasive monitoring of common health risks associated with blood pressure, life style, and medication. Its analysis and reporting tools give patients and their healthcare team access to real-time health information for treatment planning, evaluation, and management. The company offers UFIT, an automated wrist sphygmography system with computer controls that measures various signs, including blood pressure, mean arterial pressure, pulse rate, and pulse rate variability from a single digital signal acquired passively with an inflatable cuff at the wrist. It also provides Healthanywhere, a software-based, remote patient monitoring application that runs on Windows PC and Blackberry platforms. Healthanywhere solution provides for the continuum of care from wellness promotion to self-managed care, including monitoring of chronic diseases, such as congestive heart failure, hypertension, diabetes, asthma, and obesity. Biosign Technologies Inc. was incorporated in 2004 and is headquartered in Thornhill, Canada.
Recipharm was established in Sweden in 1995 and has since grown to become a leading Contract Development and Manufacturing Organisation (CDMO). Headquartered in Stockholm, we employ nearly 5 000 people and the Recipharm B-share (RECI B) is listed on NASDAQ Stockholm. For over 20 years we have focussed on supporting pharmaceutical companies in taking their products from early development through to commercial manufacturing. Throughout the entire product lifecycle, we are there for our clients. Time and time again, we have delivered innovative solutions.
BSI was founded by Judith C. McDowall in 1985 to prepare documentation for FDA regulatory submissions. BSI began preparing peer reviewed technical reports for the National Toxicology Program in 1989. We obtained and have retained this prestigious